DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...

For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...

Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings tomorrow after the bell. Here’s what investors should know. DexCom met analysts’ revenue expectations last quarter, reporting ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Shares in Dexcom plunged in extended trading Thursday after the medical devices company ...

New CEO of Dexcom, Jake Leach, joined MobiHealthNews at the JPM Healthcare Conference to discuss his leadership priorities, ...